Skip to main content

Advertisement

SpringerLink
Log in

The effects of mammalian target of rapamycin inhibitors on serum uric acid levels in renal transplant patients

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Backgrounds/Aims

Elevated uric acid (UA) levels are frequently observed after renal transplantation. We investigated the consequences of shifting from calcineurin inhibitors (CNI) to mammalian target of rapamycin inhibitors (mTORi) on UA levels and graft functions.

Methods

Ninety-six patients were enrolled. Main points of interest were changes in UA and glomerular filtration rate (GFR).

Results

Mean age of the whole population was 39 ± 11 years (18–73), and 64.2 % were male. Patients were stratified into two groups according to their CNI type prior to the switch as cyclosporin A (CsA) or tacrolimus (Tac). Patients that were switched from CsA had a mean GFR of 49 ± 18 ml/min and serum UA level of 7.4 ± 1.8 mg/dl at the pre-switch period. Mean GFR increased to 53 ± 22 ml/min (p = 0.03), and UA levels decreased to 6.2 ± 1.6 mg/dl at the final visit (p < 0.001). In the Tac group, pre-switch mean GFR was 59 ± 28 ml/min and serum UA level 6.6 ± 2.6 mg/dl. In this group, mean GFR increased to 63 ± 28 ml/min (p = 0.03) and UA levels decreased to 6.2 ± 2.1 at the last visit (p < 0.001).

Conclusion

Switch from CNI to mTORi-based regimen provides better control of UA levels and improves renal functions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA (2006) Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 82:1153–1162

    Article  PubMed  Google Scholar 

  2. Zoppini G, Targher G, Chonchol M et al (2012) Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care 35:99–104

    Article  PubMed  CAS  Google Scholar 

  3. Kawano Y (2011) Uric Acid and blood pressure. Circ J 75:2755–2756

    Article  PubMed  CAS  Google Scholar 

  4. Kaya EB, Yorgun H, Canpolat U et al (2010) Serum uric acid levels predict the severity and morphology of coronary atherosclerosis detected by multidetector computed tomography. Atherosclerosis 213:178–183

    Article  PubMed  CAS  Google Scholar 

  5. Li Q, Yang Z, Lu B et al (2011) Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol 10:72

    Article  PubMed  CAS  Google Scholar 

  6. Latif W, Karaboyas A, Tong L et al (2011) Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol 6:2470–2477

    Article  PubMed  CAS  Google Scholar 

  7. Ford ES (2011) Uric acid and mortality from all-causes and cardiovascular disease among adults with and without diagnosed diabetes: findings from the National Health and Nutrition Examination Survey III Linked Mortality Study. Diabetes Res Clin Pract 93:84–86

    Article  Google Scholar 

  8. Haririan A, Nogueira JM, Zandi-Nejad K et al (2010) The independent association between serum uric acid and graft outcomes after kidney transplantation. Transplantation 89:573–579

    Article  PubMed  CAS  Google Scholar 

  9. Kalantar E, Khalili N, Hossieni MS, Rostami Z, Einollahi B (2011) Hyperuricemia after renal transplantation. Transpl Proc 43:584–585

    Article  CAS  Google Scholar 

  10. Kim KM, Kim SS, Han DJ, Yang WS, Park JS, Park SK (2010) Hyperuricemia in kidney transplant recipients with intact graft function. Transpl Proc 42:3562–3567

    Article  CAS  Google Scholar 

  11. Saglam F, Celik A, Sarioglu S et al (2008) Hyperuricemia influences chronic cyclosporine nephropathy. Transpl Proc 40:167–170

    Article  CAS  Google Scholar 

  12. Haririan A, Metireddy M, Cangro C et al (2011) Association of serum uric acid with graft survival after kidney transplantation: a time-varying analysis. Am J Transpl 11:1943–1950

    Article  CAS  Google Scholar 

  13. Karbowska A, Boratynska M, Kusztal M, Klinger M (2009) Hyperuricemia is a mediator of endothelial dysfunction and inflammation in renal allograft recipients. Transpl Proc 41:3052–3055

    Article  CAS  Google Scholar 

  14. Akalin E, Ganeshan SV, Winston J, Muntner P (2008) Hyperuricemia is associated with the development of the composite outcomes of new cardiovascular events and chronic allograft nephropathy. Transplantation 86:652–658

    Article  PubMed  Google Scholar 

  15. Sert M, Celik A, Kural K et al (2011) Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience. Ren Fail 33:789–794

    Article  PubMed  CAS  Google Scholar 

  16. Sayin B, Karakayali H, Colak T et al (2009) Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion. Transpl Proc 41:2789–2793

    Article  CAS  Google Scholar 

  17. Pöge U, Gerhardt T, Stoffel-Wagner B, Sauerbruch T, Woitas RP (2011) Validation of the CKD-EPI formula in patients after renal transplantation. Nephrol Dial Transpl 26:4104–4108

    Article  Google Scholar 

  18. Sonoda H, Takase H, Dohi Y, Kimura G (2011) Uric acid levels predict future development of chronic kidney disease. Am J Nephrol 33:352–357

    Article  PubMed  CAS  Google Scholar 

  19. Kim KM, Kim SS, Yun S et al (2011) Uric acid contributes to glomerular filtration rate deterioration in renal transplantation. Nephron Clin Pract 118:136–142

    Article  Google Scholar 

  20. Gagliardi AC, Miname MH, Santos RD (2009) Uric acid: a marker of increased cardiovascular risk. Atherosclerosis 202:11–17

    Article  PubMed  CAS  Google Scholar 

  21. Goicoechea M, de Vinuesa SG, Verdalles U et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5:1388–1393

    Article  PubMed  CAS  Google Scholar 

  22. Yildiz A, Yilmaz R, Demirbag R, Gur M, Bas MM, Erel O (2007) Association of serum uric acid level and coronary blood flow. Coron Artery Dis 18:607–613

    Article  PubMed  Google Scholar 

  23. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26:269–275

    Article  PubMed  CAS  Google Scholar 

  24. Lyngdoh T, Marques-Vidal P, Paccaud F et al (2011) Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS ONE 6:19901

    Article  Google Scholar 

  25. Feig DI (2011) Uric acid and hypertension. Semin Nephrol 31:441–446

    Article  PubMed  CAS  Google Scholar 

  26. Rodrigues TC, Maahs DM, Johnson RJ et al (2010) Serum uric acid predicts progression of subclinical coronary atherosclerosis in individuals without renal disease. Diabetes Care 33:2471–2473

    Article  PubMed  CAS  Google Scholar 

  27. Bae MH, Lee JH, Lee SH et al (2011) Serum uric acid as an independent and incremental prognostic marker in addition to N-terminal pro-B-type natriuretic peptide in patients with acute myocardial infarction. Circ J 75:1440–1447

    Article  PubMed  CAS  Google Scholar 

  28. Jalal DI, Rivard CJ, Johnson RJ et al (2010) Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transpl 25:1865–1869

    Article  CAS  Google Scholar 

  29. Mazali FC, Mazzali M (2011) Uric acid and transplantation. Semin Nephrol 31:466–471

    Article  PubMed  CAS  Google Scholar 

  30. Mazzali M, Kim YG, Suga S et al (2001) Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 2001(71):900–905

    Article  Google Scholar 

  31. Perico N, Codreanu I, Caruso M, Remuzzi G (2005) Hyperuricemia in kidney transplantation. Contrib Nephrol 147:124–131

    PubMed  CAS  Google Scholar 

  32. Kanbay M, Akcay A, Huddam B et al (2005) Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients. Transpl Proc 37:3119–3120

    Article  CAS  Google Scholar 

  33. Maharaj S, Assounga AG (2010) Conversion of cyclosporine to sirolimus before 12 months is associated with marked improvement in renal function and low proteinuria in a South African renal transplant population. Exp Clin Transpl 8:14–18

    Google Scholar 

  34. Bumbea V, Kamar N, Ribes D et al (2005) Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transpl 20:2517–2523

    Article  CAS  Google Scholar 

  35. Claes K, Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H (2011). Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol Dial Transpl. 26 May 2011

  36. Morales JM, Andrés A, Dominguez-Gil B et al (2003) Tubular function in patients with hypokalemia induced by sirolimus after renal transplantation. Transpl Proc 2003(35):154–156

    Article  Google Scholar 

  37. Stallone G, Infante B, Pontrelli P et al (2011) Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplantation 91:997–1004

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Prof. Evert J. Dorhout Mees and for his critical review of the manuscript.

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Nephrology, Ege University, School of Medicine, 35100, Bornova, Izmir, Turkey

    Ozkan Gungor, Fatih Kircelli, Mehmet Nuri Turan, Erhan Tatar & Huseyin Toz

  2. Division of Nephrology, Tepecik Research and Training Hospital, Izmir, Turkey

    Mehmet Tanrisev

  3. Department of General Surgery, Tepecik Research and Training Hospital, Izmir, Turkey

    Cem Tugmen

Authors
  1. Ozkan Gungor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehmet Tanrisev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fatih Kircelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mehmet Nuri Turan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cem Tugmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Erhan Tatar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Huseyin Toz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ozkan Gungor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gungor, O., Tanrisev, M., Kircelli, F. et al. The effects of mammalian target of rapamycin inhibitors on serum uric acid levels in renal transplant patients. Int Urol Nephrol 45, 547–552 (2013). https://doi.org/10.1007/s11255-012-0214-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-012-0214-0

Keywords

Search

Navigation